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Summary
  Mitochondria have long been known to play a critical role in maintaining the bioenergetic status 
of cells under physiological conditions. Mitochondria produce large amounts of free radicals, and 
mitochondrial oxidative damage can contribute to a range of degenerative conditions including 
cardiovascular diseases (CVDs). Although the molecular mechanisms responsible for mitochon-
drion-mediated disease processes are not correctly understood, oxidative stress seems to play an 
important role. Consequently, the selective inhibition of mitocondrial oxidative damage is an obvi-
ous therapeutic strategy. This review considers the process of CVD from a mitochondrial perspec-
tive and provides a summary of the following areas: reactive oxygen species (ROS) production and 
its role in pathophysiological processes such as CVD, currently available antioxidants and possible 
reasons for their efficacy and inefficacy in ameliorating oxidative stress-mediated diseases, and re-
cent developments in mitochondria-targeted antioxidants that concentrate on the matrix-facing 
surface of the inner mitochondrial membrane. These mitochondrion-targeted antioxidants have 
been developed by conjugating the lipophilic triphenylphosphonium cation to antioxidant moieties 
such as ubiquinol. These compounds pass easily through biological membranes and, due to their 
positive charge, they accumulate several-hundred-fold within mitochondria. In this way they pro-
tect against mitochondrial oxidative damage and show potential as a future therapy for CVDs.
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Background
In physiological conditions a homeostatic balance exists be-
tween the formation of reactive oxygen species (ROS) and 
their elimination by endogenous antioxidant-scavenging 
compounds and enzymes [1]. Oxidative stress occurs when 
this balance is disrupted by excessive production of ROS, 
such as superoxide (O2˙
–), hydrogen peroxide (H2O2), and 
hydroxyl radicals (˙HO), peroxynitrite (ONOO–), and/or in-
adequate antioxidant defenses [2], including those caused 
by superoxide dismutase (SOD), catalase, vitamins C and E, 
and reduced glutathione (GSH). Both processes can lead to 
cardiovascular diseases (CVDs). The free-radical hypothesis 
for vascular dysfunction postulates that ROS can lead to a 
modification of lipids, proteins, and nucleic acids which, in 
turn, contributes to the etiology of the disease [3]. However, 
this perspective has been challenged in recent years by the 
recognition that these molecules can play a role in signal 
transduction [4]. This process has come to be known as “re-
dox cell signaling”, which refers to how ROS and reactive ni-
trogen species (RNS) can lead to the activation of pathways 
that control cell differentiation and apoptosis [5].
Over the last decade, the management of CVDs in exper-
imental animals has improved remarkably, without a sim-
ilar achievement being noted in humans. Thus there is a 
continuing search for more effective antioxidants that can 
counteract the oxidative stress induced in CVD, such as 
atherosclerosis and hypertension. The mitochondrial re-
spiratory chain in the inner mitochondrial membrane is a 
major intracellular source of ROS [6], indicating that a spe-
cific action of antioxidants on the mitochondrial respira-
tory chain may constitute an important mechanism of car-
diovascular protection.
ROS can cause nonspecific damage to different macro-
molecules leading to alteration or loss of cellular function. 
Therefore it is conceivable that mitochondria are more vul-
nerable to oxidative damage than other cellular organelles. 
In fact, mitochondria are continuously exposed to ROS and 
accumulate oxidative damage more rapidly than the rest of 
the cell, in particular because ROS are highly reactive and 
short-lived [7]. For these reasons, mitochondrial dysfunc-
tion disrupts the function of cells, tissues, and organs and 
contributes to a wide range of diseases. The recognition of 
mitochondria as an arbiter in the life and death of cells has 
highlighted the need to develop antioxidants and other cy-
toprotective agents that are targeted to mitochondria.
Mitochondrial oxidative damage and dysfunction contrib-
ute to a number of cell pathologies and have particular rel-
evance to CVDs such an atherosclerosis and hypertension. 
Studies seeking to counteract the deleterious effects of ROS 
have shown antioxidants such as a-tocopherol, ubiquinol, 
and N-acetylcysteine to decrease mitochondrial oxidative 
damage in different models [8–11]. However, as these com-
pounds do not significantly accumulate within mitochon-
dria, their effectiveness remains limited [12], which makes 
increasing the antioxidant capacity of the mitochondrial 
compartment a therapeutic objective. Yet, to be pharma-
ceutically viable, a small-molecule antioxidant is required, 
and so there has been a recent impulse in research efforts 
to develop mitochondrion-targeted antioxidants. One ap-
proach to addressing these challenges is to target antioxi-
dants to mitochondria through conjugation to a lipophilic 
cation, such as triphenylphosphonium (TPP), which is cell-
permeable and considerably potent in reducing intracellu-
lar ROS and thereby preventing cell death [13,14].
MechanisMs of ros Production
ROS are important secondary messengers that are gener-
ated in response to different types of environmental stress. 
At lower levels of ROS/RNS, damage to key targets in the 
mitochondria, such as mtDNA, is prevented by intramito-
chondrial antioxidant defenses. Oxidative stress is a state in 
which excess ROS overwhelm endogenous antioxidant sys-
tems. ROS have distinct functional effects on each cell type 
in the vasculature and exert both physiological and patho-
physiological influence.
In nearly all diseases in which mitochondrial dysfunction 
has a contribution, a major cause of the damage it causes 
are the ROS that it produces, either directly or as a second-
ary consequence of other malfunctions [15–17]. The prox-
imal ROS is O2
–, produced by the respiratory chain, prob-
ably at complexes I and III [15–17], although it does have 
other sources within the mitochondria. O2˙
– itself is not 
particularly reactive [18] and it can react with aconitase to 
release ferrous iron [19]. O2
– can increase the rate of for-
mation of H2O2, which react with ferrous iron to form the 
highly reactive ˙HO. Mitochondrial ROS cause damage to 
different cellular structures, thereby disrupting mitochon-
drial function [18–20]. There are a series of mitochondri-
al antioxidant defenses for intercepting ROS and minimiz-
ing oxidative damage, but excessive production of ROS or 
disruption of the antioxidant defenses leads to extensive 
oxidative damage to the mitochondria [16]. As mitochon-
drial oxidative damage is either a primary or significant 
secondary cause of cell damage and death in degenerative 
diseases, a general therapeutic approach to decrease mito-
chondrial oxidative damage could be applied in a range of 
clinical situations [16,21].
ROS generated in the vasculature include O2˙
–, H2O2, hypo-
chlorous acid (HOCl), OH, and singlet oxygen (1O2). One 
of the most important ROS in the vasculature is O2˙
– [22]. 
In addition, the formation of ONOO- has been implicated 
in CVDs. Multiple enzymatic systems produce O2˙
– and its 
derivatives in the vasculature, including NADPH oxidases, 
xanthine oxidase (XO), nitric oxide synthases (NOS), my-
eloperoxidase (MPO), and mitochondria. Indeed, leakage 
of electrons from the mitochondrial electron transport chain 
(ETC) is the main source of ROS, particularly O2˙
– [23].
RNS have also been implicated in cell damage and death. 
NOS catalyses the synthesis of NO, which may react with O2˙
– 
to produce ONOO–. In fact, ONOO– has been implicated in 
CVD-inducing mitochondrial damage and, by association, 
apoptosis [24]. Therefore, with respect to CVD, the regu-
lation of mitochondrial functions by NO acquires further 
relevance when taking into account the effects of this mol-
ecule on electron transfer, energy-transducing processes, 
and oxyradical production in mitochondria [25].
The balance between these sources of ROS depends on the 
physiological and pathophysiological states of the organism 
and it is often difficult to identify the source of ROS gen-
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eration. It is known, however, that ROS have an important 
regulatory function [5]. In fact, ROS/RNS can lead to the 
activation of pathways that control cell differentiation and 
apoptosis, both of which are mechanisms of particular rel-
evance to CVDs. Hence, a basal or total concentration of 
ROS, especially at the level of the mitochondria, is essential 
for basic cell signaling processes. In other words, all ROS are 
not created equal, with compartmentalization and concen-
tration gradients being fundamentally important.
ROS production in mitochondria occurs at several sites of 
the electron-transport chain. Importantly, it is increasing-
ly clear that each of the sites can be regulated. Thus, in the 
light of redox cell signaling, the identification of physiolog-
ical regulators of mitochondrial ROS production is of great 
importance. Several molecules/factors have been put for-
ward as regulators of mitochondrial ROS production, in-
cluding an elevated inner membrane potential, Ca2+, and 
NO [26]. Beyond the electron-transport chain, the TCA de-
hydrogenases, specifically 2-oxoglutarate dehydrogenase 
and pyruvate dehydrogenase, have been shown to gener-
ate ROS when the NADH/NAD+ ratio is high. Complex III 
of the electron transport chain is another site of high ROS 
production.
oxidative stress: daMage to Mitochondria
Inherited dysfunction of the mitochondrial oxidative phos-
phorylation system is increasingly recognized as a CVD in 
humans, and mitochondrial diseases have been associated 
with mutations of mitochondrial DNA [27], including mi-
tochondrial ATP synthase [28]. Mitochondrial ROS can 
cause damage to mitochondrial proteins, lipids, and DNA, 
thereby disrupting mitochondrial function and causing 
ROS to flow into the cytosol [18-20]. Mitochondrial DNA 
(mtDNA) is particularly susceptible to modification by 
ROS/RNS [29] because a) mtDNA is in close proximity to 
the site of ROS/RNS production, b) mtDNA lacks histone 
proteins, which can protect it from oxidative damage, and 
c) mitochondrial polymerases lack specificity for base exci-
sion and are themselves modified by ROS, which can lead 
to changes in polymerase function and increased mutation 
rates in mtDNA.
The diseases resulting of familial mitochondrial DNA de-
letions and mutations are not as common as those from 
nuclear DNA defects. This may be because mitochondria 
contain several copies of their genome; hence, continuous 
fusion of mitochondria mixes modified genes with normal 
genes. Most isolated defects of ATP synthase are associated 
with alterations in the biosynthesis of the enzyme and can 
be caused by mutations in subunit genes or in ancillary pro-
teins essential for assembly of the enzyme.
The recent discovery that acute and chronic stress in the 
cells leads to structural and functional impairments of mi-
tochondria has redefined the role of mitochondria in dis-
ease etiology [13,30] and is of a special relevance to CVDs. 
In fact, the accumulation of mtDNA damage over a lifetime 
may increase one’s susceptibility to the development of a 
pathology. Mitochondrial dysfunction triggers signaling cas-
cades for cell necrosis and apoptosis and leads to organ fail-
ure and diseases. Although the list of mitochondrion-related 
diseases is growing rapidly and includes cancer, heart failure, 
diabetes, obesity, stroke, neurodegenerative diseases, and 
aging, they all share the common features of disturbances 
of mitochondrial Ca2+, ATP, or ROS metabolism [30]. Some 
studies have shown that mitochondrial dysfunction contrib-
utes to the progression of neurodegenerative diseases such 
as Parkinson’s and to strokes [31]. Myocardial ischemia-re-
perfusion injury also leads to mitochondrial Ca2+ overload, 
which subsequently leads to uncontrollable ROS generation 
and opening of the mitochondrial permeability transition 
pore [30], which ultimately induces apoptosis. Therefore, 
compounds that minimize mitochondrial Ca2+ overload, de-
crease mitochondrial ROS accumulation, and promote mi-
tochondrial energy production are all potentially useful in 
the treatment of the above-mentioned conditions.
As mitochondria represent the major site for the genera-
tion of cellular oxidative stress and play a key role in me-
diating programmed cell death (apoptosis), damage to 
mtDNA may be an important contributor to human aging, 
cancer, and CVD by leading to alterations in membrane 
permeability, modification of protein structure, and func-
tional changes.
Whereas ROS and RNS are capable of targeting a variety 
of subcellular components, mitochondria are continually 
exposed to ROS and accumulate oxidative damage more 
rapidly than the rest of the cell. In fact, the mitochondri-
al membrane, proteins, and mtDNA appear to be partic-
ularly sensitive to oxidative and nitrosative damage [32]. 
Mitochondrial oxidative damage has been implicated in 
clinically relevant situations, including CVDs such as isch-
emia-reperfusion injury and neurodegenenerative diseases, 
having been found to contribute to their pathophysiology by 
disrupting mitochondrial function. Although the extent of 
mitochondrial oxidative stress in vivo remains unclear, its im-
portance has been demonstrated in mice lacking Mn-SOD, 
which die shortly after birth [33], while mice lacking Cu Zn-
SOD, the cytosolic form of the enzyme, survive [34].
Vascular pathologies are multifactorial, but it is clear that 
mitochondrial dysfunction contributes to the pathophysiol-
ogy of these diseases. Studies have shown that ROS induce 
a variety of effects, including preferential and sustained 
mtDNA damage, altered mitochondrial transcript levels 
and mitochondrial protein synthesis, and lowered mito-
chondrial redox potentials in vascular cells [35]. ROS and 
RNS have been implicated in atherogenesis, and increased 
oxidative stress is a shared feature among many CVD risk 
factors, mediating post-translational modifications of mito-
chondrial proteins that can result in their activation (e.g. 
cytochrome c, aconitase) [36]. It is important to point out 
that exogenous and endogenous sources of ˙NO inhibit 
mitochondrial respiration (O2 consumption), resulting in 
greater O2˙
– production but also promoting O2 diffusion 
into tissues, thereby decreasing the “steepness” of the O2 
gradient from the vascular lumen as well as controlling dif-
ferent transcription factors such as hypoxia-inducible fac-
tor (HIFa) [37].
Mitochondrial damage can alter the capacity of the cell to 
generate energy, redox signaling, and a variety of important 
functions regulated by mitochondrial oxidant generation 
and response, thus mediating changes in cell function that 
may not be directly related to cellular energy. For example, 
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it has been shown that cardiac mitochondria that sustain 
ischemic injury are more sensitive (complex IV activity) to 
changes in NO concentration than controls [38]. ROS gen-
erated in the mitochondrial respiratory chain have been 
proposed as intermediate, secondary messengers to the ac-
tivation of NF-kB [39]. Hence the relative balance between 
the stimuli of mitochondrial ROS production and the con-
comitant accumulation of organelle damage can ultimately 
influence cellular response and function, and the cellular 
response to increased oxidative stress may in turn initiate 
CVD. Consequently, excessive production of mitochondri-
al ROS or disruption to the antioxidant defenses leads to 
extensive oxidative damage to mitochondria [16]. As mi-
tochondrial oxidative damage is either a primary cause or 
a significant secondary factor leading to cell damage and 
death, a general therapy for decreasing mitochondrial oxi-
dative damage should be effective in a range of clinical sit-
uations [16,21]. Therefore, mitochondrial damage may 
serve as a general, yet direct, index or predictor of mito-
chondrial dysfunction.
antioxidants and MechanisMs
The term antioxidant is not clearly defined and, according to 
its use in the literature, may refer to an array of compounds 
with a range of mechanisms of action. Halliwell [40] has 
proposed the following practical definition: “an antioxidant 
is any substance that, when present at concentrations lower 
than those of an oxidizable substrate, significantly delays or 
prevents oxidation of that substrate”. There is an abundance 
of oxidizable substrates in the cell, including proteins, lip-
ids, carbohydrates and DNA. Thus, antioxidants may work 
to prevent the formation of ROS or to detoxify them, in ad-
dition to scavenging ROS or their precursors.
Antioxidants are central to the redox balance in the hu-
man body. They do not act in isolation, but synergistical-
ly. Primary endogenous antioxidant defenses prevent ROS 
formation, whether by removing ROS precursors or by in-
hibiting catalysts such as GSH peroxidase and catalase. 
Secondary antioxidants react with ROS that have already 
formed, either removing or inhibiting them; for example, 
vitamins C and E. Endogenous antioxidant defenses exist 
in a number of locations, both intracellularly (on the cell 
membrane) and extracellularly [10,11,41]. Types of anti-
oxidants include, for example, antioxidant vitamins (e.g. 
ascorbic acid, a-tocopherol, b-carotene), inorganic anti-
oxidants (e.g. selenium), synthetic antioxidants (e.g. bu-
tylated hydroxyanisole (BHA), butylated hydroxytoluene 
(BHT), prolyl gallate, 2,4,6-trimethylphenol), and a range 
of plant-derived polyphenols.
Intracellular antioxidants
The SOD enzymes are a family of metalloenzymes which 
promote the rapid conversion of O2˙
– to H2O2. Three forms 
of SOD are recognized to be important: copper-zinc SOD 
(cytoplasm), manganese SOD (mitochondria), and extra-
cellular SOD (extracellular matrix). Catalase and GSH per-
oxidase, an enzyme which requires the presence of reduced 
GSH in order to act, catalyse the conversion of H2O2 to H2O. 
GSH contains thiol (sulfydryl) groups and also exerts a di-
rect antioxidant activity through the donation of hydrogen 
ions, by which it repairs damaged DNA. Oxidative stress on 
and modulation of GSH/GSSG (GSSG, glutathione disul-
fide) levels also up-regulate gene expression of several oth-
er antioxidant proteins, such as manganese SOD, GSH per-
oxidase, thioredoxine, and methallothionein.
Membrane antioxidants
An alternative spectrum of antioxidants is necessary for the 
hydrophobic lipid interior of membranes. Fat-soluble vitamin 
E (a-tocopherol) is the most important antioxidant in this 
environment [42]. b-carotene, lycopene, and co-enzyme Q 
have also been implicated as membrane antioxidants. Lipid-
soluble antioxidants are important in preventing membrane 
polyunsaturated fatty acids from undergoing lipid peroxida-
tion, which leads to loss of membrane integrity.
Extracellular antioxidants
ROS may also be present in the extracellular compartment, 
especially as a result of neutrophil activation. The plasma 
and red-cell components of blood both act as antioxidants; 
red cells have a copper-zinc, SOD-dependent pathway for 
the inactivation of O2˙
–, and catalase and GSH peroxidase 
for dealing with H2O2, while a number of metal-binding plas-
ma proteins, including apotransferrin, lactoferrin, and ce-
ruloplasmin, have an important function as antioxidants. 
Albumin is also effective via its oxidizable thiol group, which 
permits the scavenging of ROS and non-radical molecules 
and the binding of reactive transition metal ions. A num-
ber of important smaller molecules that are present in the 
plasma act as secondary antioxidants. These include vita-
min E, vitamin C, uric acid, and bilirubin.
Mechanisms of antioxidant action are best understood in 
the context of their clinical and biochemical effects on ROS 
[10,11,43]. Three processes are involved in the formation 
of lipid-derived ROS: initiation, propagation, and termi-
nation. Chain-breaking antioxidants interrupt this process 
by preventing propagation on the radical chain or by ter-
minating it. a-tocopherol is a classic example of a chain-
breaking antioxidant. The antioxidant enzyme SOD catal-
yses the conversion of O2˙
– to H2O2. H2O2 can be detoxified 
by the Se-dependent GSH (GPx) and by catalase. The de-
toxification of H2O2 is particularly important because the 
reaction of H2O2 with transition metals can lead to the for-
mation of OH.
In summary, increasing the antioxidant capacity of the mito-
chondrial compartment is a potential therapy, but depends 
on a small-molecule antioxidant if it is to be pharmaceu-
tically viable [44]. However, small-molecule antioxidants 
will spread around the body, with only a small fraction be-
ing consumed by the mitochondria, which is the case of 
the antioxidant vitamin E, which produces no benefits in 
the treatment of Parkinson’s diseases [45]. An explana-
tion for this disappointing result may be a combination of 
poor uptake into the body and limited delivery to the mi-
tochondria [44,46].
Mitochondrial antioxidant defenses
Mitochondria may limit the effects of ROS via small-mole-
cule antioxidants, including GSH, ascorbic acid, and vita-
min E [47]. The antioxidant enzyme MnSOD converts O2˙
– 
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to H2O2. The mitochondrial isoform of GSH peroxidase 
and the thioredoxine-dependent enzyme peroxiredoxin 
III both detoxify H2O2. Alternatively, H2O2 is capable of dif-
fusing from the mitochondria into the cytoplasm. The mi-
tochondrial GSH pool is different from that of the cytosol 
and is maintained in its reduced state by a mitochondrial 
isoform of GSH reductase. This enzyme requires NADPH, 
which is produced within the mitochondria by the NADP-de-
pendent isocitrate dehydrogenase and through a ∆µH+-de-
pendent transhydrogenase. Within the mitochondrial phos-
pholipid bilayer, the fat-soluble antioxidants vitamin E and 
coenzyme Q both prevent lipid peroxidation, while coen-
zyme Q also recycles vitamin E and is itself regenerated by 
the respiratory chain. The mitochondrial isoform of phos-
pholipid hydroperoxide GPx degrades lipid peroxides with-
in the mitochondrial inner membrane.
Mitochondrial-targeted antioxidants
Mitochondria have an important role in cell signaling and 
so contribute to both adaptation to oxidative stress and 
the development of cardiovascular conditions such as isch-
emia-reperfusion injury, neurodegenerative diseases, dia-
betes, and atherosclerosis [48]. However, available antioxi-
dants have not proven to be especially effective against this 
range of disorders. It is possible that they do not reach the 
relevant sites of ROS generation, especially if mitochondria 
are the primary source of ROS.
Mitochondria have long been known to play a critical role 
in maintaining the bioenergetic status of cells under phys-
iological conditions, and are therefore relevant targets for 
drug-delivery strategies. Hence there is considerable inter-
est in developing strategies to target molecules with thera-
peutic potential for mitochondria [49,50]. One approach 
to addressing these challenges is to target antioxidants to 
mitochondria by conjugation to a lipophilic cation, such 
as triphenylphosphonium (TPP) [14,51]. This procedure 
leads to orally bioavailable molecules which accumulate in 
the cell, are driven by the plasma membrane potential, and 
accumulate further into the mitochondria where the anti-
oxidant moiety protects from oxidative stress. The electron 
transport generates a proton gradient that drives the pro-
duction of ATP by ATP synthase. Thus, a negative potential 
of 150-180 mV is generated across the inner mitochondrial 
membrane. The mitochondrial outer membrane is perme-
able to small molecules; the inner membrane thus repre-
sents the major barrier for drug delivery to the mitochon-
dria. This high potential gradient across the mitochondrial 
inner membrane can be exploited to deliver lipophilic cat-
ions to the mitochondria.
Several features of lipophilic cations make them effective 
at delivering antioxidants to the mitochondria: They can 
pass directly through phospholipid bilayers without requir-
ing a specific uptake mechanism, and they accumulate sub-
stantially within the mitochondria owing to their high mem-
brane potential. Lipophilic cations move without difficulty 
through phospholipid bilayers because the activation en-
ergy for moving lipohilic cations through the hydrophobic 
barrier of a biological membrane is far lower than for oth-
er cations. Hence, by attaching a compound to a lipophilic 
cation, it is possible to deliver it selectively to mitochondria 
within cells [52,53]. The aim is to make hybrid molecules in 
which the lipophilic cation delivers a bioactive “passenger” 
to mitochondria within cells, thereby enabling the rational 
manipulation of mitochondrial function in vivo [53,54]. The 
ability of mitochondria to accumulate modified lipophilic 
cations has been exploited as a potential therapy by which 
cancer cells are killed selectively [55,56], as said cells have a 
higher mitochondrial membrane potential than non-trans-
formed cells, leading to the greater accumulation of lipo-
philic cations [57,58]. Lipophilic cations have been modi-
fied in various ways in order to promote cancer cell death 
through their linking to toxic compounds [58–61].
Mitochondria are a site of significant oxidative damage in 
clinical circumstances [62], and several antioxidants, such 
as vitamin E, ubiquinol, N-acetylcysteine, SOD mimetics, 
and spin traps, have been shown to protect them against 
such damage [62,63]. Therefore, targeting an antioxidant 
to the mitochondrial matrix should increase its protection 
against oxidative damage [53,55]. By covalently attaching a 
TPP cation to the antioxidant tocopherol moiety of vitamin 
E, the antioxidant is delivered selectively to mitochondria 
[53] and protects the mitochondria from oxidative damage 
more effectively than vitamin E (a-tocopherol) itself.
TPP-based, mitochondrially targeted antioxidants: 
mitoquinone
In principle, a wide range of antioxidants could be target-
ed to mitochondria by conjugation to the TPP moiety, and 
antioxidants targeted to all components of the intramito-
chondrial ROS cascade have been developed (Figure 1). 
Antioxidants have the potential to block oxidative dam-
age and redox signaling, and exogenous ubiquinones have 
been widely used for this purpose in mitochondrial studies. 
As lipid peroxidation is important in many forms of mito-
chondrial oxidative damage, and because the alkylTPP con-
jugates are strongly associated with the mitochondrial in-
ner membrane, focus until now has been on antioxidants 















Figure 1.  Using lipophilic cations to target 
compounds to mitochondria enables 
reagents to be delivered selectively 
to mitochondria within cells. 
Lipophilic cations accumulate within 
the mitochondria are driven by the 
membrane potential and can pass 
through lipid bilayers easily as their 
positive charge is delocalized over an 
extended area.
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These molecules are based on the predominant human form 
of endogenous ubiquinone, coenzyme Q10 (CoQ10), which 
is synthesized in the mitochondrial inner membrane and 
comprises a ubiquinone head group attached to a tail of 
10 five-carbon isoprenoid units. The ubiquinone moiety is 
redoxactive, accepting two electrons and two protons in its 
reduction to a ubiquinol, while the extremely hydrophobic 
tail ensures that within the cell it is almost exclusively asso-
ciated with phospholipid bilayers. The redox activity of the 
ubiquinone moiety enables it to act as a mobile electron car-
rier in the mitochondrial inner membrane, where it is re-
duced to a ubiquinol by several membrane- bound dehy-
drogenases and oxidized back to a ubiquinone by complex 
III. Furthermore, the reduced ubiquinol form of CoQ10 has 
an important protective function as a chain-breaking anti-
oxidant, by which it terminates lipid peroxidation in phos-
pholipid bilayers. Therefore, ubiquinone supplementation 
is a promising therapeutic strategy in human pathology, as 
it may both stimulate oxidative phosphorylation, by com-
plementing any defects in respiration, and protect against 
oxidative damage. However, this duality complicates exper-
imental interpretation, as all effects of CoQ10 can be attrib-
uted to its interaction with oxidative phosphorylation, oxi-
dative damage, or redox signaling pathways.
Given the known antioxidant properties of ubiquinone, sev-
eral studies have been undertaken to prepare and test an 
analogous to endogenous ubiquinone. MitoQ has been used 
to prevent mitochondrial oxidative damage and to demon-
strate the involvement of mitochondrial ROS in signaling 
pathways. MitoQ is taken up by energized mitochondria and 
is absorbed into the matrix face of the inner mitochondri-
al membrane. Further distribution studies have shown that 
about one half of the MitoQ taken up by cells is localized in 
the mitochondrial fraction. In the respiratory chain, MitoQ 
is reduced to the active ubiquinol antioxidant by complex 
II, but it is not a good substrate for complex I or electron 
transfer flavoprotein-ubiquinone oxidoreductase.
MitoQ10 cannot restore respiration in mitochondria lack-
ing coenzyme Q, as its reduced form is poorly oxidized by 
complex III. Consequently, all the effects of MitoQ10 are 
likely to be due the accumulation of the antioxidant ubi-
quinol form [53]. Furthermore, when the ubiquinol form 
of MitoQ10 acts as an antioxidant, it is oxidized to the ubi-
quinone form, which is then rapidly reduced by complex 
II, thereby restoring antioxidant efficacy [53]. This is sig-
nificant, because the recycling of an antioxidant back to its 
active form after it has neutralized an ROS is a critical fac-
tor in the efficacy of many antioxidants [64,65].
The uptake of MitoQ10 is faster than that of TPMP, presum-
ably as a result of its greater hydrophobicity and, consequently, 
lower activation energy for passage through the plasma mem-
brane [66]. MitoQ is better tolerated than MitoVitE and in 
fact shows no toxicity at 750 nmol. However, such toxicity is 
evident at 1000 nmol. No toxic effects have been shown for 
TPMP up to 43 days, for MitoVit E up to 14 days, or for MitoQ 
up to 14 days [61]. Efficacy depends on chain length by creat-
ing and examining a series of MitoQ molecules with different 
numbers of carbons (3, 5, 10, 15) in their linker chains.
MitoQ10 and other mitochondrial-targeted antioxidants such 
as MitoE2 decrease levels of ROS, which is evident when flu-
orescence is measured [67,68]. For example, MitoQ prevents 
H2O2-induced oxidation and the formation of malondyal-
dehyde [60]. MitoQ (1 µM) blocks H2O2-induced caspase 
activation and apoptotic cell death in Jurkat cells, but has 
no effect on staurosporine-induced apoptosis in Jurkat cells 
or TNFa-induced apoptosis in cells in general. MitoQ regu-
lates important processes such as the accumulation of HIF 
in Hep3B cells in response to hypoxia [69], as well as the 
AIF factor in a model of apoptosis [70]. In several studies in 
which nitroglycerin produced an increase in ROS [71,72], 
MitoQ was shown to prevent such an increase.
Several studies have been conducted to determine the role 
of hydrophobicity in the uptake of MitoQ analogues by mi-
tochondrial membranes [54]. In these studies, analogues 
were prepared so that the length of the hydrocarbon chain 
separating the TPP and ubiquinol moieties was 3, 5, 10, 
and 15 methylene units. As expected, the octan-1-ol/saline 
partition coefficient increased as the chain length was in-
creased. Although antioxidant effects were observed with 
all analogues, MitoQ10 and MitoQ15 showed the highest ef-
ficacy in blocking ferrous iron-induced lipid peroxidation. 
In fact, the main antioxidant action of MitoQ10 is its preven-
tion of lipid peroxidation. It remains to be seen if this is the 
foremost mechanism by which MitoQ10 acts as a protective 
agent in all cell types and forms of oxidative stress. Studies 
on chain-length analogues of MitoQ have been extended 
to investigate their interactions with the mitochondrial re-
spiratory chain and ROS [52]. The reduction of MitoQ10 
affords antioxidant protection against lipid peroxidation, 
ONOO–, and O2˙
–.
Furthermore, MitoQ has been used to investigate nucleo-
tide-sensitive mitochondrial proton transport through un-
coupling proteins (UCP) [57]. In fact, O2˙
–-induced uncou-
pling was prevented by MitoQ (and MitoVit E), but not by 
the untargeted antioxidants ubiquinone, decylubiquinone, 
vitamin E, or trolox.
Due to the role of oxidative damage in telomere shorten-
ing and, consequently, in senescence and aging, the effect 
of MitoQ on telomere shortening has been investigated 
[58]. Indeed, incubation of cells under hyperoxic condi-
tions (40% O2) resulted in an increase in ROS production 
and was reduced by MitoQ. Incubation of cells with MitoQ 
lengthened the replicate life-span by approximately 40% and 
reduced hyperoxia-induced telomere shortening, indicat-
ing that reduction of oxidative stress slows telomere short-
ening and prolongs the replicate life-span of cells.
To function as a form of therapy, mitochondrial-targeted 
antioxidants must be delivered to the mitochondria with-
in patients’ cells, preferably following oral administration. 
TPP cations pass easily through phospholipid bilayers, so 
they should pass from the gut to the bloodstream and from 
there to most tissues. For example, the effect of MitoQ on 
cardiac ischemia-reperfusion injury, which is associated 
with mitochondrial oxidative damage, has been investigat-
ed in a rat model [59]. Rats drank water containing 500 µM 
MitoQ for 14 days, and at the end of the treatment period 
their hearts were removed and perfused in order to assess 
ventricular contractile function and left ventricular devel-
oped pressure (LVDP). MitoQ afforded significant pro-
tection against ischemia-reperfusion-induced decreases in 
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LVDP, whereas little or no benefit was provided by the non-
targeted ubiquinone (Q3OH) or TPP bromide. When mi-
tochondrial function was assessed in heart mitochondria 
from control and MitoQ-treated rats, MitoQ was shown to 
protect against the ischemia-reperfusion-induced decreas-
es in the respiratory control ratio (RCR), damage to com-
plex I, and decreases in aconitase activity. The amount of 
MitoQ in the hearts of treated rats was approximately 20 
pmol MitoQ/g wet weight, which corresponds with a con-
centration of 100–200 nM MitoQ.
MitoQ is currently being developed as a pharmaceutical 
product, and in phase I trials has shown to be effective when 
administered orally (1 mg/kg), while phase II trials have 
provided encouraging results with respect to Parkinson’s 
disease and Friedreich’s ataxia [73]. This work with MitoQ 
has established a satisfactory pharmaceutical profile for the 
TPP moiety and will undoubtedly be the basis for future 
pharmaceutical formulations of other mitochondrial-tar-
geted antioxidants. For this reason, we believe that MitoQ 
is a potentially effective compound to be used in the pre-
vention of CVD.
Mitochondrial daMage and cardiovascular diseases
The CVDs coronary artery disease, hypertension, congestive 
heart failure, and stroke are the leading causes of death and 
disability in the developed world [74,75]. An early progno-
sis and improved therapies for preventing and curing these 
diseases depends on an understanding of the basic patho-
physiological mechanisms of CVD. The oxidative hypothe-
sis for atherosclerosis has been critical in the development 
of our knowledge about the molecular mechanism of the 
disease. Vascular pathologies are multifactorial, but it is 
clear that mitochondrial dysfunction can contribute to the 
pathophysiology of these diseases. This appears to involve 
not only damage to the organelle and loss of bioenergetic 
function, but also disruption of mitochondrion-dependent 
redox signaling pathways.
Several lines of evidence suggest that an association exists 
between CVD development and mitochondrial function and 
damage. CVD patients present more marked mtDNA dam-
age in both the heart and the aorta than healthy controls 
[76,77]. Atherosclerotic lesions in brain microvessels from 
Alzheimer’s patients and rodent Alzheimer’s models show 
a significant presence of mtDNA deletions and abnormal-
ities (as do their endothelium and perivascular cells), sug-
gesting that the mitochondria within the vascular wall are 
a central target for oxidative stress-induced damage [78]. 
Accumulated mtDNA damage will hinder the replacement 
of respiratory chain proteins damaged by ROS production. 
These damaged proteins are more likely to generate ROS in 
an uncontrolled manner, thereby accelerating bioenergetic 
dysfunction. In this way, the role of intramitochondrial anti-
oxidants is critical, as they may alter the progression of the 
disease and prevent damage to existing proteins.
In a mouse model it has been found that previous myocardi-
al infarction is associated with increased ROS and decreased 
mtDNA copy number, mitochondrial-encoded gene tran-
scripts, and related enzymatic activities (complexes I, III, and 
IV). However, nuclear-encoded genes (complex II) and ci-
trate synthase are unaffected in said mice [79]. Cardiotoxic 
ROS generators increase mtDNA deletions and lipid peroxi-
dation in the myocardial mitochondria, and overexpression 
of mitochondrial antioxidants reverses these effects and in-
creases cardiac tolerance to ischemia [80]. Decreased vas-
cular SOD2-specific activities have been associated with 
increased exposure to several risk factors [76], increased sus-
ceptibility to ischemia/reperfusion-mediated cardiac damage 
and resistance to cardiac preconditioning [81]. Moreover, 
deficiencies in mitochondrial antioxidants and/or regu-
latory proteins that modulate mitochondrial oxidant pro-
duction have been shown to promote the onset of CVD in 
vivo, which endorses the theory that mitochondrial-gener-
ated oxidants contribute to atherogenesis [82]. Likewise, 
overexpression of mitochondrial antioxidants and/or UCPs 
has been shown to protect against the effects of ischemia/
reperfusion and oxidative stress [80,83].
CVD risk factors also cause mitochondrial damage and 
dysfunction
Accumulating evidence indicates that oxidative stress plays 
a major role in the initiation and progression of CVD [84]. 
Numerous factors, such as atherosclerosis, hypercholesterol-
emia, diabetes, tobacco exposure, age, and ischemia-reper-
fusion injury, increase the risk of CVD, and while it is not yet 
clear whether or not they alter cellular function in a similar 
fashion, a common feature is that they increase oxidative 
stress [85-86]. Moreover, it is surely more than a coincidence 
that several of said factors also appear to cause cardiovascu-
lar mitochondrial damage and/or dysfunction [76,85].
Atherosclerosis
Atherosclerosis, the primary cause of coronary artery disease 
(CAD), is a multifactorial pathology whose molecular etiol-
ogy involves the interaction of many genes and environmen-
tal factors. The majority of CVDs are a result of complica-
tions caused by atherosclerosis. Atherosclerosis is a chronic 
inflammatory disease characterized by a loss of endothelial 
cell function [87], recruitment of monocytes into the arte-
rial wall [88], and formation of lipid-foam cells. The endo-
thelium plays a key role in the initial stages of atheroscle-
rosis, especially in inducing adherence of monocytes and 
downstream signaling events. Many risk factors for athero-
sclerosis, such as increased levels of modified LDL, a smok-
ing habit, increased ROS, and diabetes, have been shown 
to damage the endothelium, and it has been hypothesized 
that dysfunction of the endothelium initiates atherosclerot-
ic lesion formation.
Endothelial cells, smooth muscle cells, and macrophages are 
sources of ROS for the oxidative modification of phospho-
lipids, and Ox-LDL can damage endothelial cells, thereby 
inducing the expression of adhesion molecules [89]. ROS 
limit the bioavailability of NO and induce inflammatory gene 
expression, cell growth/apoptosis, migration, and matrix 
reorganization, all of which are central mechanisms for the 
initiation and progression of atherosclerosis. NO signaling 
in the endothelium can be affected by a number of factors 
during atherosclerosis.
There are numerous reports of a correlation existing be-
tween DNA damage and atherosclerosis [90]. Multivariate 
analysis reveals that DNA-adduct levels are a significant pre-
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dictor of the stage of atherosclerosis, even after adjustment 
for age, smoking, obesity, and other CVD risk factors [91]. 
In other studies, higher levels of immunoreactivity against 
8-oxoG have been observed in plaques of the human ca-
rotid artery than in the adjacent inner media and non-ath-
erosclerotic mammary arteries. 8-oxoG immunostaining is 
observed in all cell types of the plaque, including macro-
phages, smooth muscle cells, and endothelium. Evidence 
suggests that there are more DNA repair mechanisms in the 
atherosclerotic plaques than in control tissues [92]. In line 
with these studies is the observation that mtDNA damage 
is increased in cardiovascular tissues in CVD patients [78]. 
However, whether this damage is an effect or initiator of 
CVD remains unclear. Animal studies have shown that vas-
cular mtDNA damage is greater in animal models of athero-
sclerosis and that this damage occurs prior to, or simultane-
ously with, the development of the disease [78].
Defects in oxidative phosphorylation from heart mitochon-
dria have been identified in strains of pigeons susceptible 
to atherosclerosis, in which the dissociation of NADH tran-
shydrogenation from ATP regulation enhanced lipid bio-
synthesis [93]. Mitochondrial respiratory dysfunction has 
also been demonstrated in myocardial mitochondria of ath-
erosclerotic swine.
Ballinger et al. 2002 [76] showed that oxidative mitochon-
drial DNA damage correlated positively with the extent 
of atherosclerotic lesions in arteries of humans and apoE 
knockout mice, and that this damage preceded the onset 
of the disease in these mice. Besides, LDL receptor knock-
out cells are more exposed to oxidative stress and are more 
susceptible to cell death due to an undermined mitochon-
drial antioxidant defense system and a higher susceptibili-
ty to mitochondrial pore transition. Thus, the LDL recep-
tor defect has two important pro-atherogenic consequences 
that sometimes manifest themselves before the disease ini-
tiates, namely, increased extracellular levels of oxidizable 
substrate (LDL) and an imbalance of cell redox processes, 
which can occur in the vascular wall where local oxidative 
stress takes place, subsequently triggering lipoprotein oxi-
dation, cell death, and atherogenesis.
In another study, Ballinger et al. demonstrated that SOD2 
mutant (SOD2–/–) mice exhibited inhibition of the respi-
ratory chain enzymes NADH-dehydrogenase (complex I) 
and succinate dehydrogenase (complex II) as well as inac-
tivation of redox-sensitive enzymes such as aconitase, ac-
companied by accumulation of oxidative mitochondrial 
DNA damage. SOD2+/– mice also exhibit a rise in O2˙
– lev-
els concomitant with a 50% decrease in MnSOD activity in 
mitochondria (compared with SOD2+/+ mice). In this way, 
these studies underline the value of mitochondrion-target-
ed antioxidants as a therapeutic tool for counteracting the 
development of atherosclerosis.
Atherosclerotic disease remains a leading cause of death in 
developed societies, and ROS play a pivotal role in athero-
genesis. Oliveira et al. [94] have shown that mitochondria 
from atherosclerosis-prone, hypercholesterolemic LDL re-
ceptor knockout mice have an oxidative phosphorylation 
efficiency similar to that of control mice, while their net 
production of ROS and susceptibility to developing mem-
brane permeability transition are both higher.
Oxidized lipids are capable of initiating diverse cellular re-
sponses through both receptor-mediated mechanisms and 
direct post-translational modification of proteins. Typically, 
exposure of cells to low concentrations of oxidized lipids 
induces cytoprotective pathways, whereas high concentra-
tions lead to apoptosis. In fact, incubation of endothelial 
cells with concentrations of oxLDL characteristic of cyto-
protection induce a mitochondrial complex I activity that 
seems to depend on the induction of oxidative stress [95]. 
Reports of oxLDL inducing the transcription and expres-
sion of SOD2 protein in human macrophage endorse the 
hypothesis that oxLDL increases mitochondrial oxidative 
stress [96]. Increased mitochondrial oxidant generation 
and decreased mitochondrial membrane potential have 
also been studied in human macrophage cells treated with 
oxLDL, in which scavengers of peroxides prevented said ef-
fects [97]. A standard consequence of increased oxidative 
stress due to exposure to ox-LDL is the breaking of the nu-
clear DNA strand, which is thought to be a signal of an in-
crease in p53 protein levels. Inhibition of macrophage ly-
sis in atherosclerotic lesions, without affecting macrophage 
apoptosis, is likely to prevent lesion progression and permit 
lesional cellularity, lesion remodeling, and regression to be 
controlled, which highlights mitochondrially targeted an-
tioxidants as a therapeutic tool in the control of hypercho-
lesterolemia and, therefore, atherosclerosis.
Treatment of mouse peritoneal macrophages with free cho-
lesterol (FC) causes a marked decrease in mitochondrial 
membrane potential, cytochrome c release, activation of 
caspase-9 and effector caspases, and elevated levels of bax 
[85]. While SOD2 activity and GSH concentration are sig-
nificantly higher in the atherosclerotic intima than in the 
media of the aorta of hyperlipidemic rabbits, SOD2 activity 
and GSH concentration are also found to be inversely relat-
ed to age and plaque size, suggesting that both are directly 
correlated and may be related to the early stages of athero-
sclerotic lesion formation [96]. Hence the effects of hyper-
cholesterolemia on SOD2 expression and activity may be 
age related and represent an early “protective” response to 
the increased mitochondrial oxidation that occurs during 
the initial events of CVD risk factor exposure and/or ath-
erogenesis. In general, free cholesterol, oxidized low-den-
sity lipoprotein, and glycated high-density lipoprotein are 
further causes of mitochondrial dysfunction and/or apopto-
sis. High-fat diets reduce the expressions of genes involved 
in free-radical scavenging (SOD1, GPX, and SOD2) and 
increase the expressions of stress-response (Hsp 70) and 
signal-transduction genes (Ras, MAPK1) in rats. However, 
while UCP-2 levels increase, UCP-3 levels remain unaffect-
ed. Antioxidant supplementation of a high-fat diet reduc-
es the magnitude of these differences [98].
Apoptosis can be induced by a number of different stress 
factors in the cardiovascular system and has been implicat-
ed in a number of chronic disorders, including atheroscle-
rosis [99,101].
Diabetes
Cardiovascular complications are the leading cause of mor-
bidity and mortality in patients with diabetes. In fact, recent-
ly it has been suggested that increased mitochondrial ROS 
production during hyperglycemia is central to the general 
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pathology of diabetes [102–105]. Therefore, mitochondri-
al ROS production and oxidative damage may contribute 
to the onset, progression, and pathological consequences 
of both type 1 and type 2 diabetes. Emerging evidence sup-
ports the hypothesis that both of these prominent features 
of type 2 diabetes are caused by mitochondrial dysfunction 
and ROS production
Hyperglycemia induces increased O2˙
–- generation in en-
dothelial cells in vitro, and studies suggest that the majority 
of this O2˙
– is produced by mitochondria [103] with some 
contribution from NADPH oxidase. In this respect it has 
been speculated that hyperglycemia increases the inner 
membrane proton gradient as a result of overproduction 
of electron donors (e.g. NADH and FADH2) by the TCA 
cycle, which is manifested in an increased production of 
O2˙
– and increased activity of antioxidant enzymes [106]. 
These same factors also prevent glucose-induced activation 
of phosphokinase C and NF-kB activation in endothelial 
cells [107]. Similarly, overexpression of SOD2 significantly 
reduces IL-1, TNFa, IFNg activation of NF-kB, and the in-
duction of iNOS in insulin-producing cells. In this sense, 
some studies have addressed the role of mitochondrial ROS 
and oxidative damage in TNF-induced apoptosis using mi-
tochondrial-targeted derivatives of vitamin E (MitoVitE), 
ubiquinol (MitoQ), and PBN (MitoPBN). These targeted 
antioxidants, MitoVit E, MitoQ, and MitoPBN, accumulate 
selectively in the mitochondrial matrix, protecting the mi-
tochondria against oxidative damage. MitoQ and MitoVit 
E protect cells from a variety of apoptotic stimuli, includ-
ing 5-fluorouracil, growth factor deprivation, and GSH de-
pletion in frataxin-depleted cells, and also inhibit H2O2-in-
duced growth factor receptor signaling [108]. These results 
confirmed the role of mitochondrial ROS in said processes 
and demonstrate that mitochondrial-targeted antioxidants 
are useful tools for determining the role of mitochondrial 
ROS in signal transduction. Therefore, mitochondrial ROS 
are critical modulators of TNF-induced apoptosis, which 
is mediated, at least in part, by a delay in the activation of 
NF-kB. This suggests that mitochondrial ROS are produced 
in response to TNF treatment and that they impede a full 
apoptotic response to TNF by enhancing NF-kB-mediated 
expression of antiapoptotic proteins.
As oxidative damage forms part of the pathophysiology of 
diabetes, there is interest in determining whether or not an-
tioxidants reduce this damage [109]. Too few large-scale, 
double-blind trials on the use of antioxidants in diabetes 
have been carried out to come to any reliable conclusions 
[109,110]. However, a few small-scale trials have pointed to-
wards the efficacy of the natural antioxidants a-tocopherol, 
ascorbate, coenzyme Q, and a-lipoic acid, although other 
trials have produced somewhat ambiguous results regard-
ing the efficacy of ascorbate and a-tocopherol [110]. These 
natural antioxidants can be administered at high doses and 
have shown some efficacy in other degenerative diseases, 
which provides a strong rationale for testing them in diabe-
tes [46], though it must be said that the uptake and distri-
bution to tissues of hydrophobic natural antioxidants such 
as coenzyme Q is often poor [111]. In addition, many oth-
er artificial antioxidants are presently in development, such 
as mimetics of SOD or peroxidase, and may be more po-
tent than natural antioxidants and possess an improved bio-
availability, pharmacokinetics, and stability [112]. However, 
these artificial antioxidants are novel drugs and will need 
to be submitted to clinical trials. Both natural and artifi-
cial antioxidants are distributed throughout the body, with 
only a small proportion reaching the mitochondria, where 
much of the oxidative damage associated with hyperglyce-
mia would seem to occur.
In relation to the use of mitochondrial-targeted antioxidants, 
and because mitochondrial oxidative damage is thought to 
be critical to the pathophysiology of diabetes, antioxidants 
that accumulate within mitochondria may offer more pro-
tection than untargeted antioxidants. As a first step toward 
testing this hypothesis, a strategy has been developed to de-
liver antioxidants to mitochondria by covalent attachment to 
the TPP cation through an alkyl chain. Importantly, the ac-
cumulation of these antioxidants by mitochondria protects 
them from oxidative damage far more effectively than untar-
geted antioxidants, suggesting that the accumulation of an-
tioxidants within mitochondria does increase their efficacy. 
Most interestingly, the compounds in question were effec-
tive in preventing cell death in fibroblasts from Friedreich’s 
ataxia patients. As cell death in this model is due to endog-
enous mitochondrial oxidative damage [113], it has been 
suggested that the accumulation of antioxidants by mito-
chondria within cells reverses mitochondrial oxidative dam-
age, and that their uptake into mitochondria makes them 
far more effective than untargeted antioxidants.
If these mitochondrial-targeted molecules are to have ther-
apeutic potential in the treatment of diabetes, then it is es-
sential that they are taken up selectively by mitochondria in 
vivo. Given that alkylTPP cations pass easily through lipid bi-
layers by means of carrier-unmediated transport, they should 
be taken up by the mitochondria in all tissues, in contrast 
to hydrophilic compounds, which rely on the tissue-specif-
ic expression of carriers for uptake [46]. Several studies in 
mice fed for several weeks with mitochondrion-targeted an-
tioxidants have shown stable steady-state concentrations in 
all the tissues assessed, including brain, heart, liver, and kid-
neys [57]. These data are consistent with the following phar-
macokinetic model: following absorption from the gut into 
the bloodstream, orally administered mitochondrial-target-
ed antioxidants are taken up into all the tissues through an 
unmediated movement through the lipid bilayer of the plas-
ma membrane, and are assisted by the plasma membrane po-
tential. From the cytosol, most of the lipophilic cations are 
driven by the large membrane potential and taken up into 
the mitochondria. After several days of feeding, the cation 
concentration within mitochondria achieves a steady-state 
distribution with circulating blood levels. At this point, the 
mitochondrial concentration is several hundred-fold high-
er than that in the bloodstream. As the mitochondrial pool 
of compound is in dynamic equilibrium, once feeding stops 
the accumulated cations re-equilibrate back into the blood-
stream and are excreted relatively rapidly.
Given that these compounds accumulate within mitochon-
dria, the intramitochondrial concentration is approximate-
ly millimolar. These concentrations are likely to fall within 
a therapeutically effective range, because mitochondri-
al-targeted antioxidants prevent oxidative damage to iso-
lated mitochondria at 1–2.5 mmol/l [60]. As these com-
pounds are further accumulated in cells, similar protective 
effects are found when cultured cells are incubated with 
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500 nmol/l to 1 µmol/l mitochondrial-targeted antioxi-
dants [114]. Therefore, oral delivery of well-tolerated dos-
es of mitochondrial-targeted antioxidants can deliver po-
tentially therapeutic concentrations to mitochondria in 
vivo. Their efficacy in preventing oxidative damage to mi-
tochondria in vivo could be tested in mouse models of mi-
tochondrial oxidative damage.
Tobacco smoke exposure
Active and passive exposure to tobacco smoke is an im-
portant cause of morbidity and mortality [114]. Multiple 
studies have shown that chronic smokers are at more risk 
of diseases related to atherosclerosis, such as coronary ob-
struction and acute myocardial infarction, and of sudden 
death. In this sense, chronic smoking causes endothelium 
dysfunction, increased oxidation of LDL-cholesterol, re-
duction of blood levels of HDL-cholesterol, and increased 
blood levels of adhesion molecules and fibrinogen, joint 
factors that can lead to platelet aggregation and, eventual-
ly, vascular spasm [115].
Tobacco smoke exposure has also been related to other car-
diac conditions. Greenspan et al. [116] demonstrated the 
acute effects of nicotine on hemodynamic and function-
al cardiac variables. Rats exposed to chronic carbon mon-
oxide, another component found in the vapor phase of 
mainstream cigarette smoke, showed an increase in their 
endothelin-1 gene expression, which induced myocardi-
al hypertrophy [117]. In addition, impairment of the left 
ventricular function, evaluated by means of transthoracic 
echocardiography, has been demonstrated in rats exposed 
to cigarette smoke for 30 days and 4 months [118]. These 
findings suggest that exposure to nicotine/tobacco smoke 
is associated with alterations of both functional and mor-
phological cardiac variables.
Cigarette smoke exposure is a principal cardiovascular risk 
factor that contributes to atherosclerosis and hypertension. 
The majority of individuals chronically exposed to tobac-
co smoke will succumb to CVD. Smoking reduces arterial 
O2 carrying capacity through increased serum carboxy-he-
moglobin levels and causes mitochondrial respiration dys-
function in cardiac cells [119]. When combined with other 
CVD risk factors (e.g. hypercholesterolemia), second-hand 
tobacco smoke exposure synergistically accelerates both mi-
tochondrial damage and atherogenesis [77]. Further illus-
tration of the link between accumulated mtDNA defects and 
susceptibility to CVD is the impact of exposure to environ-
mental tobacco smoke in utero. Gestational exposure to to-
bacco smoke in mice increases the rate of development of 
atherosclerosis as the animals mature [120].
Treatment of human monocytes and vascular smooth mus-
cle cells (VSMCs) with tobacco smoke filtrate results in loss 
of mitochondrial membrane potential, apoptosis, and ne-
crosis, effects that are prevented by N-acetylcysteine (NAC) 
treatment [121]. More recently it has been shown that rats 
treated with benzo(a)pyrene in order to induce an athero-
genic phenotype have an upregulated expression of mtD-
NA transcripts. Cultures acquired from these rats had in-
creased growth rates and shows marked enhancement of 
proliferation to serum mitogens [122]. Endothelial adap-
tive responses that accompany the chronic manifestations 
of smoke exposure include hypertension, increased endo-
thelial adhesiveness, increased vascular permeability, and 
vascular remodeling.
Studies have been developed in order to counteract the 
negative effects of tobacco in CVD. NAC prevented tobacco 
smoke-induced deltapsim disruption and apoptosis, while 
the caspase inhibitor Z-VAD.Fmk had no affect on deltap-
sim, though it did prevent apoptosis, and SOD had no ef-
fect [123], underlining mitochondria as the main target for 
ROS-mediated effects of tobacco smoke exposure.
Age
There is emerging evidence that cellular senescence contrib-
utes to the pathogenesis of human atherosclerosis. Senescent 
vascular cells accumulate in human atheroma tissues and ex-
hibit various features of dysfunction. Some epidemiological 
studies have demonstrated that, even in the absence of oth-
er risk factors (e.g. diabetes, hypertension, hypercholester-
olemia), vascular aging significantly increases cardiovascular 
morbidity [124]. Previous reports have revealed that vascular 
aging is characterized by an age-dependent decline in endo-
thelial function due to a reduced bioavailability of NO and 
increased production of ROS. Yet the mechanisms underly-
ing the process of vascular aging are still poorly understood. 
There is evidence that aging is associated with an increase in 
mtDNA damage and a decline in the expression/activity of 
mitochondrial enzymes in various organs [125]. Numerous 
mitochondrial functions decline with age and are generally 
accompanied by a concomitant reduction in OXPHOS effi-
ciency and increased mtDNA damage. Whereas studies have 
shown that aging is accompanied by both decreased ener-
getic capacity and increased mitochondrial ROS generation, 
the effects of age on mitochondrial redox signaling proper-
ties have not been studied in great detail. It is likely that, as 
happened with its energetic functions, the efficiency of the 
redox functions of the mitochondrial decline with age. It 
has also been shown that CVD risk factors such as hypercho-
lesterolemia and tobacco smoke accelerate mitochondrial 
damage [76]. Hence many CVD risk factors may act on the 
cardiovasculature by inducing mitochondrial damage and 
dysfunction, thus mediating a “premature” aging process. 
In this respect, an individual’s age during CVD risk factor 
exposure may influence disease development.
As the natural antioxidants vitamin E and CoQ are thought 
to protect mitochondria from oxidative damage in vivo, mi-
tochondrial-targeted derivatives of these molecules were ini-
tially developed to counteract oxidative stress. In vitro ex-
periments show that MitoVitE and MitoQ are rapidly and 
selectively accumulated by isolated mitochondria and by mi-
tochondria within isolated cells [57]. It is significant that the 
accumulation of these antioxidants by mitochondria protect 
them from oxidative damage far more effectively than un-
targeted antioxidants [60]. This suggests that the accumu-
lation of antioxidants within mitochondria increases their 
efficacy. Furthermore, mitochondrial-targeted antioxidants 
have also been shown to modulate the role of mitochondrial 
ROS production through putative redox signaling pathways 
[108] and to prevent telomerase shortening [58].
Aging is a slow process best studied in intact organisms. 
Therefore, for mitochondrial-targeted molecules to be used 
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as probes of mitochondrial ROS production in aging, they 
must be accumulated by mitochondria in vivo. TPP cations 
accumulate in the mitochondria of all tissue, as they can 
cross phospholipid bilayers with ease by means of carrier-
unmediated transport. This contrasts with hydrophilic com-
pounds, which often depend on tissue-specific transport 
pathways for uptake. When mice were fed mitochondrial-
targeted antioxidants for several weeks, stable-state concen-
trations were observed in all the tissues assessed, including 
the brain, heart, liver, and kidneys [55].
Ischemia-reperfusion injury
Stroke is the second most common cause of death in devel-
oped countries and one of the major causes of death and 
disability, and thus puts serious weight on public health 
systems, being the neurological disease which accounts for 
the largest number of hospitalizations. Stroke causes cellu-
lar damage related to the sharp reduction in available O2 
and to deficiencies in energy-supplying substances, which 
leads to a sharp increase in lactate production and, there-
fore, acidosis. These events reflect a marked imbalance be-
tween energy use and production. This oxidative stress in-
duces changes in Ca2+ that subsequently activate enzymes 
such as phospholypases, proteases, and nucleases, thereby 
contributing to the cell damage that produces ROS. In this 
way, during ischemia there is a decrease in mitochondrial 
oxidative phosphorylation that induces a prompt drop in 
ATP levels and an increase in the levels of ADP and AMP. 
Lactates therefore accumulate, causing extensive tissue aci-
dosis. The increase in adenine nucleotide and the decrease 
in pH block the mitochondrial pore.
When ischemia is followed by reperfusion, mitochondrial 
respiratory functions are rapidly and completely restored. 
However, a decline soon occurs in mitochondrial O2 con-
sumption in tissue subregions containing damaged cells. 
Thus, post-ischemia reperfusion induces a cascade of altera-
tions that increase the severity of damage; in fact, mitochon-
dria hydrolyze ATP when O2 is lacking in order to maintain 
the mitochondrial membrane potential. This activity destroys 
any available ATP, favors Ca2+ accumulation and increases the 
generation of ROS, which damages the mitochondria.
The first consequence of a decrease in oxidative phosphory-
lation is an increase in state-4 O2 consumption. During reox-
ygenation, cytochrome c and cardiolipin are simultaneous-
ly and rapidly released, allowing the release of cytochrome 
c from the mitochondria, which leads to cell death. This is 
evidence of the potential of mitochondria as a source of 
oxidative damage after a stroke, while ROS that burst dur-
ing reperfusion may also damage the mitochondrial DNA 
(mtDNA). Studies have revealed specific mtDNA deletion 
patterns following transient global ischemia, traumatic brain 
injury, and focal ischemia.
Therefore, mitochondrial protection may play a key role 
in strategies for treating ischemia-reperfusion injury [125] 
with the following objectives: the inhibition of ROS gener-
ation by respiratory complexes I and III, the protection of 
mitochondrial lipids, proteins, and DNA from ROS-induced 
damage in order to prevent mitochondrial membrane al-
terations, and the release of the proapoptotic signal that in-
duces cell death. Other studies describe a significant role 
for antioxidants such as taurine in ischemia-reperfusion in-
jury, with an apparent clinical function emerging in human 
trials of taurine administered prior to coronary artery by-
pass grafting and heart valve surgery [126].
conclusions
The loss of control of ROS formation in the mitochondria 
contributes to the pathology of CVD. In fact, mitochondria 
play a critical role in apoptotic cell death and cell apopto-
sis, the latter being implicated in the development of CVD. 
Accumulated knowledge regarding these mechanisms has led 
to the development of a range of strategies for developing mi-
tochondria-targeted antioxidants that prevent ROS-induced 
mitochondrial oxidative damage. The use of selective antiox-
idants to attenuate apoptotic signaling may shed light on the 
role of generalized mitochondrial redox alterations during 
cell death. Mitochondrially targeted antioxidants represent 
a potential therapy for the many diseases that involve mito-
chondrial oxidative damage. The development of transgenic 
or inbred mouse models for mitochondria-associated diseas-
es constitutes an important tool for the testing and further 
development of mitochondria-targeted therapies.
MitoQ has proved to be active in a rat model of cardiac 
ischemia-reperfusion injury and is successfully delivered 
orally to humans. However, pre-clinical studies in intact ro-
dent models and in other mammals are necessary in order 
to evaluate the effectiveness and toxicity of mitochondrial-
ly targeted antioxidants. These compounds could confirm 
the validity of this research pathway, which may bear fruit 
in clinically effective therapeutic agents. Finally, there is 
considerable scope for finely tuning the chemical biology 
of these compounds to target specific ROS and other mi-
tochondrial genes.
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